UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 9, 2003
VAXGEN, INC.
(Exact name of registrant as specified in its charter)
Delaware | ||
(State or other jurisdiction of incorporation) | ||
|
|
|
0-26483 |
| 94-3236309 |
(Commission File No.) |
| (IRS Employer Identification No.) |
|
|
|
1000 MARINA BLVD., SUITE 200, BRISBANE, CALIFORNIA 94005 | ||
(Address of registrant’s principal executive offices, including Zip Code) | ||
|
|
|
Registrant’s telephone number, including area code: (650) 624-1000 | ||
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
Number |
| Description |
99.1 |
| Office and R&D Sublease, dated August 1, 2002, by and between Cellegy Pharmaceuticals, Inc. and VaxGen, Inc. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| VAXGEN, INC. | |||
|
|
| ||
|
|
| ||
Dated: December 9, 2003 | By: | /s/ CARTER A. LEE |
|
|
|
| Carter A. Lee |
| |
|
| Senior Vice President-Finance and Administration |
| |
3
EXHIBIT INDEX
Number |
| Description |
99.1 |
| Office and R&D Sublease, dated August 1, 2002, by and between Cellegy Pharmaceuticals, Inc. and VaxGen, Inc. |
4
